Relmada Therapeutics, Inc.
RLMD
$2.77
$0.5725.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 18.10% | -22.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.90% | -4.49% | |||
| Operating Income | 43.90% | 4.49% | |||
| Income Before Tax | 43.81% | 5.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.81% | 5.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.81% | 5.88% | |||
| EBIT | 43.90% | 4.49% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 48.51% | 6.61% | |||
| Normalized Basic EPS | 48.99% | 4.25% | |||
| EPS Diluted | 48.51% | 6.61% | |||
| Normalized Diluted EPS | 48.99% | 4.25% | |||
| Average Basic Shares Outstanding | 9.15% | 0.78% | |||
| Average Diluted Shares Outstanding | 9.15% | 0.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||